Correction to: Leukemia https://doi.org/10.1038/s41375-020-0840-y, published online 29 April 2020
The article Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab, written by Estefanía García-Guerrero, Ralph Götz, Sören Doose, Markus Sauer, Alfonso Rodríguez-Gil, Thomas Nerreter, K. Martin Kortüm, José A. Pérez-Simón, Hermann Einsele, Michael Hudecek & Sophia Danhof, was originally published Online First without Open Access. After publication in volume 35, page 201–214, the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2021 and the article is forthwith distributed under the terms of the Creative Commons Attribution.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
García-Guerrero, E., Götz, R., Doose, S. et al. Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia 36, 297 (2022). https://doi.org/10.1038/s41375-021-01355-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-021-01355-6
